Compare RemeGen Co., Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 23.54% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -69.48
2
Risky -
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
HKD 16,739 Million ()
48.00
NA
0.00%
-0.07
57.96%
1.74
Revenue and Profits:
Net Sales:
5,982 Million
(Quarterly Results - Jun 2026)
Net Profit:
4,989 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.88%
0%
17.88%
6 Months
-9.79%
0%
-9.79%
1 Year
-24.01%
0%
-24.01%
2 Years
642.0%
0%
642.0%
3 Years
94.81%
0%
94.81%
4 Years
132.45%
0%
132.45%
5 Years
-23.12%
0%
-23.12%
RemeGen Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
259.61%
EBIT Growth (5y)
23.54%
EBIT to Interest (avg)
-62.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.11
Sales to Capital Employed (avg)
0.40
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.97%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
3.48
EV to EBIT
40.26
EV to EBITDA
32.52
EV to Capital Employed
4.06
EV to Sales
3.94
PEG Ratio
0.40
Dividend Yield
NA
ROCE (Latest)
10.08%
ROE (Latest)
7.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
5,981.90
740.50
707.82%
Operating Profit (PBDIT) excl Other Income
5,137.80
57.80
8,788.93%
Interest
4.90
15.10
-67.55%
Exceptional Items
-47.60
407.60
-111.68%
Consolidate Net Profit
4,988.80
370.10
1,247.96%
Operating Profit Margin (Excl OI)
844.00%
-39.40%
88.34%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 707.82% vs -55.91% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 1,247.96% vs -73.23% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,515.50
1,854.20
89.60%
Operating Profit (PBDIT) excl Other Income
480.60
-1,451.50
133.11%
Interest
76.10
78.50
-3.06%
Exceptional Items
696.40
1.70
40,864.71%
Consolidate Net Profit
769.60
-1,592.00
148.34%
Operating Profit Margin (Excl OI)
37.90%
-856.40%
89.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 89.60% vs 55.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 148.34% vs 4.66% in Dec 2024
About RemeGen Co., Ltd. 
RemeGen Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






